The Eukaryotic Translation Initiation Factor 4E (eIF4E) as a Therapeutic Target for Cancer

Sara Karaki; Claudia Andrieu; Hajer Ziouziou; Palma Rocchi

doi:10.1016/bs.apcsb.2015.09.001

The Eukaryotic Translation Initiation Factor 4E (eIF4E) as a Therapeutic Target for Cancer

Adv Protein Chem Struct Biol. 2015:101:1-26. doi: 10.1016/bs.apcsb.2015.09.001. Epub 2015 Oct 23.

Authors

Sara Karaki¹, Claudia Andrieu¹, Hajer Ziouziou¹, Palma Rocchi²

Affiliations

¹ INSERM, U1068, CRCM, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, Marseille, France; CNRS, UMR7258, Marseille, France.
² INSERM, U1068, CRCM, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, Marseille, France; CNRS, UMR7258, Marseille, France. Electronic address: palma.rocchi@inserm.fr.

Abstract

Cancer cells depend on cap-dependent translation more than normal tissue. This explains the emergence of proteins involved in the cap-dependent translation as targets for potential anticancer drugs. Cap-dependent translation starts when eIF4E binds to mRNA cap domain. This review will present eIF4E's structure and functions. It will also expose the use of eIF4E as a therapeutic target in cancer.

Keywords: Cancer; Therapeutic target; eIF4E.

Publication types

Review

MeSH terms

Eukaryotic Initiation Factor-4E / biosynthesis
Eukaryotic Initiation Factor-4E / chemistry*
Eukaryotic Initiation Factor-4E / genetics*
Humans
Molecular Targeted Therapy*
Neoplasms / genetics*
Neoplasms / therapy
Protein Conformation
RNA, Messenger / biosynthesis
Structure-Activity Relationship
Transcription, Genetic

Substances

Eukaryotic Initiation Factor-4E
RNA, Messenger